Social Media Ideas for Biosimilars

FDA OKs Immgolis as first golimumab biosimilar for UC, RA

The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis.Golimumab-sldi (Immgolis, Accord BioPharma) has been approved as a bio...

Samsung Bioepis launches Ustekinumab biosimilar in Japan with Nipro

Samsung Bioepis announced Wednesday the launch of its Ustekinumab biosimilar in Japan, marking the company’s first product debut in the country under a partnership with NIPRO Corp....

Sen. Committee Clears Drug Disclosure, Biosimilar Bills

The U.S. Senate Committee on Health, Education, Labor and Pensions on Wednesday cleared two bills for full Senate review, tackling the gap between health and patent oversight agenc...

A New Approach to Supporting Quality of Biologics

The United States Pharmacopeia (USP) is proposing a new approach for its work to support the quality and availability of selected biologic medicines. Building on decades of experie...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik]]>

FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer

By: Sabrina Serani From; targetedonc.com The FDA has approved an abbreviated new drug application (ANDA) for generic eribulin mesylate injection, offering a new therapeutic option...

<![CDATA[Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata]]>

The State of Biologics Testing Report 2026

This report is intended to inform discussion and decision making, not to prescribe solutions. Produced in collaboration with GEN, it reflects the collective voice of an industry ad...

What Data Says About Biologics-Related Ex Parte Challenges

An analysis of the 67 ex parte reexaminations used to challenge biologics patents over the last 13 years reveals that reexamination may emerge as an alternative to inter partes rev...

<![CDATA[FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Sarclisa Escena]]>

Medicare drug price rule may target under-the-skin Keytruda and Opdivo

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

Canada and India now have generic Wegovy. Here’s why the U.S. doesn’t.

Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy generics that could cost as little as $15 a month.

Ipca inks licensing agreement with Bhami Research for biologics delivery platform access

Licencing agreement grants Ipca access to Bhami Research’s proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialisation of mult...

Lower-Cost Generic Ozempic (Semaglutide) Is Now Available From Canada for U.S. Patients

Americans Can Access Affordable Generic Ozempic (Semaglutide) Through Reliable Canadian Prescription Referral Services

ASCO: Will New Drugs Demonstrate Benefits Over Generics?

ASCO: Will New Drugs Demonstrate Benefits Over Generics? Anonymous (not verified) Sun, 05/31/2026 - 14:42 pharmagather item url ASCO: Will New Drugs Demons...

Generic semaglutide to hit Canadian pharmacies this week at lower cost

Health Canada approved both Dr. Reddy's and Apotex's generic semaglutide — the active ingredient in brand-name Ozempic and Wegovy — about three weeks ago.

Generic drugmakers gain key victory in ‘skinny label’ patent case

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

Groups Tell 4th Circ. Not To Let Sandoz 'Relitigate' Enbrel

Pharmaceutical groups and the Washington Legal Foundation backed Amgen in amicus briefs Monday urging the Fourth Circuit not to revive Sandoz's antitrust claims, arguing that if Sa...

Glenmark launches generic Olanzapine injection in US

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Bruk...

Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda In India

Oral semaglutide, a glucagon-Like Peptide-1 receptor agonist (GLP-1 RA), is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes...

<![CDATA[TrumpRx Expands to Offer Generic Medications]]>

Sandoz's Patent Loss Blocks Antitrust Suit, 4th Circ. Told

Retired U.S. Circuit Judge Paul R. Michel is backing Amgen against Sandoz's Fourth Circuit appeal, arguing in an amicus brief that the final say over now-nixed allegations of block...